The Bill & Melinda Gates Foundation is investing in a pioneering biotech firm developing drugs to fight life-threatening infections.
Arsanis, headquartered in America, has raised $45 million in a new funding drive, led by the Gates Foundation. The money will be used to advance drugs that can combat the growing threat of antibiotic-resistant bacteria.
Rene Russo, the biotech’s chief executive officer hailed the “caliber of investors attracted to Arsanis” as evidence of the faith there in its work to develop “therapies to prevent and treat serious infectious diseases and mitigate the growing global health threat of antimicrobial resistance”.
